Point mutations within the fatty acid synthase type II dehydratase components HadA or HadC contribute to isoxyl resistance in Mycobacterium tuberculosis

Antimicrobial Agents and Chemotherapy

Volumn 57, Issue 1, 2013, Pages 629-632

  Gannoun Zaki, Laila ^a   Alibaud, Laeticia ^a   Kremer, Laurent ^a  

^a UNIVERSITÉ DE MONTPELLIER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BACTERIAL PROTEIN; ETHAMBUTOL; FATTY ACID SYNTHASE; FATTY ACID SYNTHASE TYPE II DEHYDRATASE; HADA PROTEIN; HADAB PROTEIN; HADABC PROTEIN; HADBC PROTEIN; HADC PROTEIN; HYDROLYASE; ISONIAZID; TIOCARLIDE; UNCLASSIFIED DRUG;

ANTIBACTERIAL ACTIVITY; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL MUTATION; COMPLEX FORMATION; CONTROLLED STUDY; GENE OVEREXPRESSION; MINIMUM INHIBITORY CONCENTRATION; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; POINT MUTATION; PRIORITY JOURNAL; WILD TYPE;

ANTITUBERCULAR AGENTS; BACTERIAL PROTEINS; DRUG RESISTANCE, BACTERIAL; FATTY ACID SYNTHETASE COMPLEX, TYPE II; GENE EXPRESSION; HYDRO-LYASES; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS; MYCOLIC ACIDS; PHENYLTHIOUREA; POINT MUTATION; PROTEIN SUBUNITS;

EID: 84872036531     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01972-12     Document Type: Article

References (20)

1. Espinal MA. 2003. The global situation of MDR-TB. Tuberculosis (Edinb.) 83: 44-51.
2. Mondal R, Jain A. 2007. Extensively drug-resistant Mycobacterium tuberculosis, India. Emerg. Infect. Dis. 13:1429-1431.
3. DeBarber AE, Mdluli K, Bosman M, Bekker LG, Barry CE, III. 2000. Ethionamide activation and sensitivity in multidrug-resistant Mycobacterium tuberculosis. Proc. Natl. Acad. Sci. U. S. A. 97:9677-9682.
4. Dover LG, Alahari A, Gratraud P, Gomes JM, Bhowruth V, Reynolds RC, Besra GS, Kremer L. 2007. EthA, a common activator of thiocarbamide-containing drugs acting on different mycobacterial targets. Antimicrob. Agents Chemother. 51:1055-1063.
5. Kordulákova J, Janin YL, Liav A, Barilone N, Dos Vultos T, Rauzier J, Brennan PJ, Gicquel B, Jackson M. 2007. Isoxyl activation is required for bacteriostatic activity against Mycobacterium tuberculosis. Antimicrob. Agents Chemother. 51:3824-3829.
6. Winder FG, Collins PB, Whelan D. 1971. Effects of ethionamide and isoxyl on mycolic acid synthesis in Mycobacterium tuberculosis BCG. J. Gen. Microbiol. 66:379-380.
7. Phetsuksiri B, Baulard AR, Cooper AM, Minnikin DE, Douglas JD, Besra GS, Brennan PJ. 1999. Antimycobacterial activities of isoxyl and new derivatives through the inhibition of mycolic acid synthesis. Antimicrob. Agents Chemother. 43:1042-1051.
8. Phetsuksiri B, Jackson M, Scherman H, McNeil M, Besra GS, Baulard AR, Slayden RA, DeBarber AE, Barry CE, III, Baird MS, Crick DC, Brennan PJ. 2003. Unique mechanism of action of the thiourea drug isoxyl on Mycobacterium tuberculosis. J. Biol. Chem. 278:53123-53130.
9. Gratraud P, Huws E, Falkard B, Adjalley S, Fidock DA, Berry L, Jacobs WR, Jr, Baird MS, Vial H, Kremer L. 2009. Oleic acid biosynthesis in Plasmodium falciparum: characterization of the stearoyl-CoA desaturase and investigation as a potential therapeutic target. PLoS One 4:e6889. doi:10.1371/journal.pone. 0006889.
10. Kremer L, Douglas JD, Baulard AR, Morehouse C, Guy MR, Alland D, Dover LG, Lakey JH, Jacobs WR, Jr, Brennan PJ, Minnikin DE, Besra GS. 2000. Thiolactomycin and related analogues as novel antimycobacterial agents targeting KasA and KasB condensing enzymes in Mycobacterium tuberculosis. J. Biol. Chem. 275:16857-16864.
11. Larsen MH, Vilcheze C, Kremer L, Besra GS, Parsons L, Salfinger M, Heifets L, Hazbon MH, Alland D, Sacchettini JC, Jacobs WR, Jr. 2002. Overexpression of inhA, but not kasA, confers resistance to isoniazid and ethionamide in Mycobacterium smegmatis, M. bovis BCG and M. tuberculosis. Mol. Microbiol. 46:453-466.
12. Sacco E, Covarrubias AS, O'Hare HM, Carroll P, Eynard N, Jones TA, Parish T, Daffe M, Backbro K, Quemard A. 2007. The missing piece of the type II fatty acid synthase system from Mycobacterium tuberculosis. Proc. Natl. Acad. Sci. U. S. A. 104:14628-14633.
13. Brown AK, Bhatt A, Singh A, Saparia E, Evans AF, Besra GS. 2007. Identification of the dehydratase component of the mycobacterial mycolic acid-synthesizing fatty acid synthase-II complex. Microbiology 153:4166-4173.
14. Belardinelli JM, Morbidoni HR. 2012. Mutations in the essential FAS II β-hydroxyacyl ACP dehydratase complex confer resistance to thiacetazone in Mycobacterium tuberculosis and Mycobacterium kansasii. Mol. Microbiol. 86:568-579.
15. Slama N, Leiba J, Eynard N, Daffe M, Kremer L, Quemard A, Molle V. 2011. Negative regulation by Ser/Thr phosphorylation of HadAB and HadBC dehydratases from Mycobacterium tuberculosis type II fatty acid synthase system. Biochem. Biophys. Res. Commun. 412:401-406.
16. Sambandamurthy VK, Derrick SC, Hsu T, Chen B, Larsen MH, Jalapathy KV, Chen M, Kim J, Porcelli SA, Chan J, Morris SL, Jacobs WR, Jr. 2006. Mycobacterium tuberculosis DeltaRD1 DeltapanCD: a safe and limited replicating mutant strain that protects immunocompetent and immunocompromised mice against experimental tuberculosis. Vaccine 24:6309-6320.
17. Cantaloube S, Veyron-Churlet R, Haddache N, Daffe M, Zerbib D. 2011. The Mycobacterium tuberculosis FAS-II dehydratases and methyltransferases define the specificity of the mycolic acid elongation complexes. PLoS One 6:e29564. doi:10.1371/journal.pone.0029564.
18. Veyron-Churlet R, Bigot S, Guerrini O, Verdoux S, Malaga W, Daffe M, Zerbib D. 2005. The biosynthesis of mycolic acids in Mycobacterium tuberculosis relies on multiple specialized elongation complexes interconnected by specific protein-protein interactions. J. Mol. Biol. 353:847-858.
19. Veyron-Churlet R, Guerrini O, Mourey L, Daffe M, Zerbib D. 2004. Protein-protein interactions within the fatty acid synthase-II system of Mycobacterium tuberculosis are essential for mycobacterial viability. Mol. Microbiol. 54:1161-1172.
20. Alahari A, Trivelli X, Guerardel Y, Dover LG, Besra GS, Sacchettini JC, Reynolds RC, Coxon GD, Kremer L. 2007. Thiacetazone, an antitubercular drug that inhibits cyclopropanation of cell wall mycolic acids in mycobacteria. PLoS One 2:e1343. doi:10.1371/journal.pone.0001343.